Masitinib
How it works: Reaching inflammation inside the brain →
In development for MS or related diseases. No approval for these conditions is recorded in the bank.
- Molecule type
- Small molecule
- Mechanism (ChEMBL)
- Fibroblast growth factor receptor 3 inhibitor|Platelet-derived growth factor receptor inhibitor|Stem cell growth factor receptor inhibitor
- Targets
- Fibroblast growth factor receptor 3, Mast/stem cell growth factor receptor Kit, Platelet-derived growth factor receptor
Approvals
None recorded.
Safety communications
None recorded.
Trials
Key trials
Large trials with a reported result on their main goal.
- Masitinib, phase 3
Completed · Phase 3 · Progressive MS · Main goal met
- Masitinib, phase 3
Completed · Phase 3 · Progressive MS · Main goal met
Other trials (4)
Completed small trials, dose-finding studies and trials in other diseases.
- AB20009
Terminated · Phase 3 · Progressive MS · stopped_other
- MAXIMS
Suspended · Phase 3 · Progressive MS · ongoing
- Masitinib, phase 3
Terminated · Phase 3 · Relapsing MS · stopped_other
- Masitinib, phase 2
Completed · Phase 2 · Progressive MS · Main goal not met
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error